recombinant lactoferrin (VEN120) / Ventria - LARVOL DELTA

Secondary Acute Myeloid Leukemia transformed from chronic myelomonocytic leukemia is strongly resistant to venetoclax but demonstrates sensitivity to anti-GM-CSF lenzilumab immunotherapy (ASH 2025) - "Published reports and our South AustralianRegistry revealed poorer median overall survival of sAML (3.5-3.7 months) and CR/CRi rates (0-33%)compared to newly-diagnosed previously untreated AML receiving azacitidine and venetoclax therapy(median OS 14.7 months, CR/CRi 66.4%)...Colony suppression by LENZ was significantly greater than VEN or AZA aloneor in combination (52.7±7.0 colonies vs. VEN 120.0±23.6; P=0.0004 or AZA 126.0±23.1; P=0.0002, VEN/AZA98.7±17.2; P=0.007), but comparable to VEN/AZA/LENZ triple therapy... The ability of secondary AML to form colonies may be driven by an autocrine source of pro-inflammatory cytokine production, revealing a vulnerability that can be targeted by precisionimmunotherapy. We report for the first time that venetoclax resistant secondary AML transformed fromCMML show sensitivity to antibody-directed GM-CSF blockade. Indeed, encouraging real-world clinicaldata of a patient with secondary AML safely receiving..."

IO biomarker • Acute Myelogenous Leukemia • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • ANXA5 • CD33 • CSF2 • NPM1 • PTPRC